This phase 1/2 open-label study reports a planned update of the safety and efficacy of durvalumab in patients with locally advanced/metastatic urothelial carcinoma who had progressed on, were ineligible for, or refused prior chemotherapy.
This study addressed toxic effects and time to treatment failure in patients with melanoma treated with nivolumab plus ipilimumab.
A woman in her 60s with a history of metastatic breast cancer presented with a 3-month history of a progressive, asymptomatic cutaneous eruption of nontender discrete erysipeloid plaques on her chest and back. What is your diagnosis?
This phase 2 clinical trial evaluated the safety and efficacy of individualized adaptive stereotactic body radiotherapy for liver tumors in patients who have preexisting liver dysfunction.
This cohort study of patients with early-stage colorectal cancer examines whether prediagnostic systemic inflammation is associated with at-diagnosis sarcopenia and explores whether these factors interact to predict cancer survival.
A woman in her 60s presented with multiple painful cutaneous nodules and a history of IgGκ multiple myeloma. What is your diagnosis?
This cross-sectional survey study examines financial distress and cost expectations among patients with cancer presenting for anticancer therapy.
This cohort study evaluates baseline surveillance methods for cancer detection in patients with Li-Fraumeni syndrome.
This meta-analysis assesses the clinical utility of whole-body magnetic resonance imaging in 13 cohorts of germline TP53 mutation carriers.
In this cohort study of patients with Lynch syndrome with colorectal, endometrial, and/or ovarian cancer, mutation genes and types are evaluated for their association with age at cancer onset.
This population-based study evaluates the risk of cancer in families who are positive for Amsterdam criteria for Lynch syndrome.
This cohort study of patients with Li-Fraumeni syndrome assesses the diagnostic yield and false-positive rate of an annual surveillance program including whole-body magnetic resonance imaging in patients identified as carriers of TP53 gene mutations.
This prospective study of surveillance strategies uses a whole-body screening program, including whole-body magnetic resonance imaging, in carriers of germline mutations in TP53.
This interim analysis of an ongoing randomized clinical trial presents preliminary findings regarding use of whole-body magnetic resonance imaging for cancer surveillance of TP53 mutation carriers.